Physician profile
Dan Chaksupa
NPI 1992819676
$7,589.64
in general payments reported to CMS, 2019-2025
43 companies · $653 in 2025
The $653 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,288 · 2020: $1,125 · 2021: $1,400 · 2022: $1,308 · 2023: $1,046 · 2024: $769 · 2025: $653.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,469.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,468.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,011.92 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $665.73 | 2019-2025 | Evenity, Repatha, Prolia |
| Lilly USA, LLC | $564.21 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $477.90 | 2019-2025 | Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $452.93 | 2019-2025 | Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $377.28 | 2019-2025 | Jardiance, Synjardy |
| Janssen Pharmaceuticals, INC | $238.95 | 2019-2022 | |
| Pfizer INC. | $210.07 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $201.45 | 2019-2022 | |
| Astellas Pharma US INC | $192.26 | 2019-2025 | Veozah |
| Abbott Laboratories | $190.37 | 2021-2024 | Freestyle Libre 3, Octrode, Proclaim |
| Merck Sharp & Dohme LLC | $185.84 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Novartis Pharmaceuticals Corporation | $162.53 | 2019-2025 | |
| Bausch Health US, LLC | $155.59 | 2019-2023 | Aplenzin, Wellbutrin |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $153.14 | 2019-2025 | Xifaxan |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dan Chaksupa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.